Previous close | 16.30 |
Open | 16.20 |
Bid | 16.20 x N/A |
Ask | 16.60 x N/A |
Day's range | 16.20 - 16.60 |
52-week range | 5.80 - 39.80 |
Volume | |
Avg. volume | 0 |
Market cap | 648.277M |
Beta (5Y monthly) | 1.48 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Silk Road Medical (SILK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.